ResearcherSecond Affiliated Hospital of Zhejiang UniversityNo recent work listed

Sinan Lu

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5111620814. Sources: OpenAlex.

Their work

Papers: 3
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper

Papers 3

The MyD88 inhibitor, ST2825, induces cell cycle arrest and apoptosis by suppressing the activation of the NF‑κB/AKT1/p21 pathway in pancreatic cancer. Co-author DOI 10.3892/or.2023.8585 ↗
Inhibitor of Pancreatic Cancer by RHIL1RA-Letter. Co-author DOI 10.1158/1078-0432.ccr-16-3270 ↗
Therapeutic efficacy and safety of S-1-based combination therapy compare with S-1 monotherapy following gemcitabine failure in pancreatic cancer: a meta-analys… Co-author DOI 10.1038/srep36944 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Sheng Yan · 1 shared paper, 2023 · strength 0.22
- Paper The MyD88 inhibitor, ST2825, induces cell cycle arrest and apoptosis by suppressing the activation of the NF‑κB/AKT1/p2… DOI 10.3892/or.2023.8585 ↗
Shusen Zheng · 2 shared papers, 2016–2017 · strength 0.17
- Paper Inhibitor of Pancreatic Cancer by RHIL1RA-Letter. DOI 10.1158/1078-0432.ccr-16-3270 ↗
- Paper Therapeutic efficacy and safety of S-1-based combination therapy compare with S-1 monotherapy following gemcitabine fai… DOI 10.1038/srep36944 ↗
Weilin Wang · 2 shared papers, 2016–2017 · strength 0.17
- Paper Inhibitor of Pancreatic Cancer by RHIL1RA-Letter. DOI 10.1158/1078-0432.ccr-16-3270 ↗
- Paper Therapeutic efficacy and safety of S-1-based combination therapy compare with S-1 monotherapy following gemcitabine fai… DOI 10.1038/srep36944 ↗
Dongkai Zhou · 1 shared paper, 2016 · strength 0.05
- Paper Therapeutic efficacy and safety of S-1-based combination therapy compare with S-1 monotherapy following gemcitabine fai… DOI 10.1038/srep36944 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.